tiprankstipranks
Trending News
More News >
Lyell Immunopharma (LYEL)
NASDAQ:LYEL
US Market

Lyell Immunopharma (LYEL) AI Stock Analysis

Compare
111 Followers

Top Page

LY

Lyell Immunopharma

(NASDAQ:LYEL)

40Neutral
Lyell Immunopharma's overall stock score reflects significant financial challenges, particularly due to the lack of revenue generation and operational losses. Technical analysis indicates a bearish trend, with the stock price below key moving averages and momentum indicators in oversold territory. Valuation metrics are also concerning, with a negative P/E ratio and no dividend yield, highlighting the need for strategic improvements to attract investor interest.
Positive Factors
Financial Stability
Lyell ended 4Q24 with $383.5 million in cash, which management expects to provide an operational runway into 2027.
Regulatory Approval
RMAT designation for LYL314 is a positive sign in turbulent times at the FDA.
Negative Factors
Competitor Landscape
The CD19-targeted CAR-T space is considered crowded and may not support another entrant with the current under $3 billion aggregated annual sales across competitors.
Financial Performance
Lyell reported a net loss of $0.69 per share, which was worse than the analyst's estimate of a net loss of $0.18 per share.

Lyell Immunopharma (LYEL) vs. S&P 500 (SPY)

Lyell Immunopharma Business Overview & Revenue Model

Company DescriptionLyell Immunopharma (LYEL) is a biotechnology company focused on developing innovative cell therapies for cancer. The company leverages its expertise in T-cell biology and genetic engineering to create products aimed at enhancing the functionality and durability of T-cells, with the goal of improving outcomes for patients with solid tumors. Lyell operates within the biopharmaceutical sector, offering advanced therapeutic solutions designed to address unmet medical needs in oncology.
How the Company Makes MoneyLyell Immunopharma primarily generates revenue through collaboration agreements and strategic partnerships with other biotechnology and pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development or regulatory goals, and potential royalties from product sales. As a pre-commercial stage company, Lyell does not yet have products on the market, so its earnings are largely dependent on external funding sources, including research grants and investments from venture capital firms. Additionally, Lyell may engage in licensing agreements that allow other companies to use its proprietary technologies, further contributing to its revenue streams.

Lyell Immunopharma Financial Statement Overview

Summary
Lyell Immunopharma faces significant financial challenges, mainly due to zero revenue generation and persistent operational losses. The balance sheet is stronger with low debt, but cash flow is strained, relying heavily on financing. This reflects high operational risk and a need for strategic changes.
Income Statement
30
Negative
Lyell Immunopharma has faced significant challenges in revenue generation, with revenue dropping to zero in the latest year. The company has consistently reported negative net income, resulting in negative net profit margins. The absence of revenue and persistent losses indicate financial difficulties in scaling operations or commercializing products.
Balance Sheet
60
Neutral
The balance sheet shows a strong equity position with a low debt-to-equity ratio, reflecting financial prudence. However, the decline in stockholders' equity over the years may indicate operational challenges. The equity ratio remains healthy, suggesting solid capital management despite operational losses.
Cash Flow
40
Negative
Lyell Immunopharma's cash flow statement highlights significant operating cash outflows due to ongoing losses. While free cash flow remains negative, the company has maintained a consistent level of cash reserves. The ability to generate positive cash flow from financing activities has been crucial in sustaining operations.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
61.00K130.00K84.68M10.65M7.76M
Gross Profit
61.00K130.00K68.22M-3.88M281.00K
EBIT
-3.31M-247.01M-183.12M-214.78M-211.94M
EBITDA
-3.31M-226.76M-166.65M-199.94M-207.64M
Net Income Common Stockholders
-342.99M-234.63M-4.75M-285.50M-198.53M
Balance SheetCash, Cash Equivalents and Short-Term Investments
370.53M546.22M640.15M614.79M612.62M
Total Assets
490.86M750.03M937.56M1.13B908.28M
Total Debt
50.99M63.17M67.70M67.82M54.57M
Net Debt
-54.60M-82.48M-55.85M-226.01M-85.83M
Total Liabilities
108.03M95.08M104.31M197.62M189.84M
Stockholders Equity
382.82M654.95M833.25M929.79M718.44M
Cash FlowFree Cash Flow
-162.86M-166.38M-193.83M-191.75M-212.35M
Operating Cash Flow
-162.39M-163.69M-169.56M-126.25M-160.87M
Investing Cash Flow
122.42M184.05M-11.54M-121.57M-273.52M
Financing Cash Flow
1.33M1.74M10.63M401.24M476.79M

Lyell Immunopharma Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.46
Price Trends
50DMA
0.55
Negative
100DMA
0.59
Negative
200DMA
0.94
Negative
Market Momentum
MACD
-0.02
Negative
RSI
48.21
Neutral
STOCH
52.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LYEL, the sentiment is Neutral. The current price of 0.46 is above the 20-day moving average (MA) of 0.45, below the 50-day MA of 0.55, and below the 200-day MA of 0.94, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 48.21 is Neutral, neither overbought nor oversold. The STOCH value of 52.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LYEL.

Lyell Immunopharma Risk Analysis

Lyell Immunopharma disclosed 69 risk factors in its most recent earnings report. Lyell Immunopharma reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Lyell Immunopharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$5.35B3.96-42.60%2.86%17.58%1.27%
48
Neutral
$150.13M-54.21%-78.55%-0.92%
45
Neutral
$122.55M-23.91%-13.92%-2.86%
41
Neutral
$142.82M123.38%1.84%43.40%
40
Neutral
$136.21M-66.10%-53.08%-40.31%
39
Underperform
$111.76M-31.94%30.76%
39
Underperform
$174.10M-25.95%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
LYEL
Lyell Immunopharma
0.46
-2.08
-81.89%
FATE
Fate Therapeutics
1.31
-2.91
-68.96%
ADCT
ADC Therapeutics
1.44
-3.01
-67.64%
NKTX
Nkarta
2.09
-5.01
-70.56%
SEER
Seer
2.05
-0.19
-8.48%
FDMT
4D Molecular Therapeutics
3.76
-23.00
-85.95%

Lyell Immunopharma Corporate Events

Product-Related AnnouncementsExecutive/Board ChangesBusiness Operations and Strategy
Lyell Immunopharma’s LyFE Center Begins IMPT-314 Production
Neutral
Apr 1, 2025

Following FDA clearance, Lyell Immunopharma’s LyFE manufacturing center in Bothell, Washington, is now producing IMPT-314 for a Phase 1/2 clinical trial targeting relapsed/refractory aggressive large B-cell lymphoma. The company plans to close its West Hills facility, acquired in 2024, resulting in a workforce reduction of approximately 73 employees and expected costs of $3.0 million to $4.0 million. Additionally, Chief Business Officer Matthew Lang announced his resignation, effective April 13, 2025, but will remain as an advisor until September 30, 2025. Lyell maintains its financial guidance, projecting a net cash use of $175 million to $185 million in 2025, ensuring operational runway into 2027.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.